Trajectories of functioning after remission from anxiety disorders: 2-year course and outcome predictors

Psychological Medicine

Volumn 44, Issue 3, 2014, Pages 593-605

  Iancu, S C ^a   Batelaan, N M ^b   Zweekhorst, M B M ^a   Bunders, J F G ^a   Veltman, D J ^b   Penninx, B W J H ^b   Van Balkom, A J L M ^b  

^a ATHENA INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anxiety disorder; functioning; longitudinal; prediction; symptom remission

Indexed keywords

ADAPTIVE BEHAVIOR; ADULT; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; CHRONIC DISEASE; COGNITION; COMORBIDITY; DAILY LIFE ACTIVITY; DEPRESSION; DISABILITY; EMPLOYMENT; EPIDEMIOLOGY; FEMALE; HUMAN; HUMAN RELATION; MALE; NETHERLANDS; OUTCOME ASSESSMENT; PERSONALITY; PHYSIOLOGY; PSYCHOLOGIC TEST; PSYCHOLOGICAL ASPECT; REMISSION; SOCIAL PARTICIPATION; STATISTICS; TIME;

ACTIVITIES OF DAILY LIVING; ADAPTATION, PSYCHOLOGICAL; ADULT; ALCOHOLISM; ANXIETY DISORDERS; CHRONIC DISEASE; COGNITION; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DEPRESSIVE DISORDER; DISABILITY EVALUATION; EMPLOYMENT; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INTERPERSONAL RELATIONS; INTERVIEW, PSYCHOLOGICAL; MALE; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE); PERSONALITY; REMISSION INDUCTION; SOCIAL PARTICIPATION; TIME FACTORS;

EID: 84891781954     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291713001050     Document Type: Article

References (80)

1. Acarturk C, Smit F, de Graaf R, van Straten A, ten Have M, Cuijpers P (2009). Economic costs of social phobia: a population-based study. Journal of Affective Disorders 115, 421-429.
2. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V, Lepine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J, Arbabzadeh-Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M, Domingo-Salvany A, Ferrer M, Joo SS, Martinez-Alonso M, Matschinger H, Mazzi F, Morgan Z, Morosini P, Palacin C, Romera B, Taub N, Vollebergh WAM (2004a). Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica. Supplementum 420, 38-46.
3. Alonso J, Ferrer M, Gandek B, Ware JE, Aaronson NK, Mosconi P, Rasmussen NK, Bullinger M, Fukuhara S, Kaasa S, Leplege A (2004b). Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Quality of Life Research 13, 283-298.
4. Ballenger JC (1999). Clinical guidelines for establishing remission in patients with depression and anxiety. Journal of Clinical Psychiatry 60, 29-34.
5. Ballenger JC (2001). Treatment of anxiety disorders to remission. Journal of Clinical Psychiatry 62, 5-9.
6. Bandelow B (2006). Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectrums 11, 21-28.
7. Batelaan N, de Graaf R, van Balkom A, Vollebergh W, Beekman A (2007a). Thresholds for health and thresholds for illness: panic disorder versus subthreshold panic disorder. Psychological Medicine 37, 247-256.
8. BatelaanN, SmitF, deGraafR, van BalkomA, Vollebergh W, Beekman A (2007b). Economic costs of full-blown and subthreshold panic disorder. Journal of Affective Disorders 104, 127-136.
9. Batelaan NM, deGraaf R, Penninx BWJH, van Balkom AJLM, Vollebergh WAM, Beekman ATF (2010a) The 2-year prognosis of panic episodes in the general population. Psychological Medicine 40, 147-157.
10. Batelaan NM, de Graaf R, Spijker J, Smit JH, van Balkom AJLM, Vollebergh WAM, Beekman ATF (2010b). The course of panic attacks in individuals with panic disorder and subthreshold panic disorder: a population-based study. Journal of Affective Disorders 121, 30-38.
11. Beard C, Moitra E, Weisberg RB, Keller MB (2010a). Characteristics and predictors of social phobia course in a longitudinal study of primary-care patients. Depression and Anxiety 27, 839-845.
12. Beard C, Weisberg RB, Keller MB (2010b). Health-related quality of life across the anxiety disorders: findings from a sample of primary care patients. Journal of Anxiety Disorders 24, 559-564.
13. Beck AT, Brown G, Epstein N, Steer RA (1988). An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology 56, 893-897.
14. Bijl RV, Ravelli A (2000). Current and residual functional disability associated with psychopathology: findings from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychological Medicine 30, 657-668.
15. Buist-Bouwman MA, Ormel J, de Graaf R, Vollebergh WAM (2004). Functioning after a major depressive episode: complete or incomplete recovery? Journal of Affective Disorders 82, 363-371.
16. Chopra PK, Couper JW, Herrman H (2004). The assessment of patients with long-term psychotic disorders: application of the WHO Disability Assessment Schedule II. Australian and New Zealand Journal of Psychiatry 38, 753-759.
17. Chwastiak LA, Von Korff M (2003). Disability in depression and back pain: evaluation of the World Health Organization Disability Assessment Schedule (WHO DAS II) in a primary care setting. Journal of Clinical Epidemiology 56, 507-514.
18. Cody MW, Teachman BA (2010). Post-event processing and memory bias for performance feedback in social anxiety. Journal of Anxiety Disorders 24, 468-479.
19. Cohen J (1988). Statistical Power Analysis for the Behavioral Sciences. Lawrence Erlbaum Associates: Hillsdale, NJ.
20. Comer JS, Blanco C, Hasin DS, Liu S-M, Grant BF, Turner JB, Olfson M (2011). Health-related quality of life across the anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Journal of Clinical Psychiatry 72, 43-50.
21. Costa PT, McCrae RR (1995). Domains and facets: hierarchical personality assessment using the revised NEO personality inventory. Journal of Personality Assessment 64, 21-50.
22. Eguchi M, Noda Y, Nakano Y, Kanai T, Yamamoto I, Watanabe N, Lee K, Ogawa S, Ietsugu T, Sasaki M, Chen JW, Furukawa TA (2005). Quality of life and social role functioning in Japanese patients with panic disorder. Journal of Nervous and Mental Disease 193, 686-689.
23. Fehm L, Pelissolo A, Furmark T, Wittchen HU (2005). Size and burden of social phobia in Europe. European Neuropsychopharmacology 15, 453-462.
24. Fydrich T, Dowdall D, Chambless DL (1992). Reliability and validity of the Beck Anxiety Inventory. Journal of Anxiety Disorders 6, 55-61.
25. Goodwin RD, Faravelli C, Rosi S, Cosci F, Truglia E, de Graaf R, Wittchen HU (2005). The epidemiology of panic disorder and agoraphobia in Europe. European Neuropsychopharmacology 15, 435-443.
26. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JRT, Ballenger JC, Fyer AJ (1999). The economic burden of anxiety disorders in the 1990s. Journal of Clinical Psychiatry 60, 427-435.
27. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jonsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen H-C, Stovner LJ, Vallat J-M, van den Bergh P, van Os J, Vos P, Xu W, Wittchen H-U, Jonsson B, Olesen J; CDBE2010Study Group (2011). Cost of disorders of the brain in Europe 2010. European Neuropsychopharmacology 21, 718-779.
28. Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J (2007). Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. International Clinical Psychopharmacology 22, 167-174.
29. Jorm AF, Griffiths KM, Christensen H, Medway J (2002). Research priorities in mental health, part 1: an evaluation of the current research effort against the criteria of disease burden and health system costs. Australian and New Zealand Journal of Psychiatry 36, 322-326.
30. Keller MB (2003). The lifelong course of social anxiety disorder: a clinical perspective. Acta Psychiatrica Scandinavica. Supplementum 417, 85-94.
31. Keller MB (2006). Social anxiety disorder clinical course and outcome: review of Harvard/Brown Anxiety Research Project (HARP) findings. Journal of Clinical Psychiatry 67, 14-19.
32. Kessler RC (2003). The impairments caused by social phobia in the general population: implications for intervention. Acta Psychiatrica Scandinavica. Supplementum 417, 19-27.
33. Konrad J, Stanisława S, Joanna K (2010). Factors accounting for psychosocial functioning in patients with low back pain. European Spine Journal 19, 613-623.
34. Lecrubier Y, Judge R (1997). Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatrica Scandinavica 95, 153-160.
35. Leon AC, Portera L, Weissman MM (1995). The social costs of anxiety disorders. British Journal of Psychiatry 166, 19-22.
36. Lieb R, Becker E, Altamura C (2005). The epidemiology of generalized anxiety disorder in Europe. European Neuropsychopharmacology 15, 445-452.
37. Lochner C, Mogotsi M, du Toit PL, Kaminer D, Niehaus DJ, Stein DJ (2003). Quality of life in anxiety disorders: a comparison of obsessive-compulsive disorder, social anxiety disorder, and panic disorder. Psychopathology 36, 255-262.
38. Marks IM, Mathews AM (1979). Brief standard self-rating for phobic patients. Behaviour Research and Therapy 17, 263-267.
39. Mavissakalian MR, Perel JM, Talbott-Green M, Sloan C (1998). Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. Biological Psychiatry 43, 848-854.
40. Melse JM, Essink-Bot ML, Kramers PGN, Hoeymans N (2000). A national burden of disease calculation: Dutch disability-adjusted life-years. American Journal of Public Health 90, 1241-1247.
41. Mendlowicz MV, Stein MB (2000). Quality of life in individuals with anxiety disorders. American Journal of Psychiatry 157, 669-682.
42. Michelson D, Lydiard B, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD (1998). Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. American Journal of Psychiatry 155, 1570-1577.
43. Olatunji BO, Cisler JM, Tolin DF (2007). Quality of life in the anxiety disorders: a meta-analytic review. Clinical Psychology Review 27, 572-581.
44. Ormel J, Oldehinkel AJ, Nolen WA, Vollebergh W (2004). Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects. Archives of General Psychiatry 61, 387-392.
45. Ormel J, Vonkorff M, Vandenbrink W, Katon W, Brilman E, Oldehinkel T (1993). Depression, anxiety, and social disability show synchrony of change in primary care patients. American Journal of Public Health 83, 385-390.
46. Penninx BWJH, Beekman ATF, Smit JH, Zitman FG, Nolen WA, Spinhoven P, Cuijpers P, de Jong PJ, van Marwijk HWJ, Assendelft WJJ, van der Meer K, Verhaak P, Wensing M, de Graaf R, Hoogendijk WJ, Ormel J, van Dyck R (2008). The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. International Journal of Methods in Psychiatric Research 17, 121-140.
47. Perini SJ, Slade T, Andrews G (2006). Generic effectiveness measures: sensitivity to symptom change in anxiety disorders. Journal of Affective Disorders 90, 123-130.
48. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R (1998). Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Archives of General Psychiatry 55, 1010-1016.
49. Rodriguez BF, Bruce SE, Pagano ME, Keller MB (2005). Relationships among psychosocial functioning, diagnostic comorbidity, and the recurrence of generalized anxiety disorder, panic disorder, and major depression. Journal of Anxiety Disorders 19, 752-766.
50. Rubin HC, Rapaport MH, Levine B, Gladsjo JK, Rabin A, Auerbach M, Judd LL, Kaplan R (2000). Quality of well being in panic disorder: the assessment of psychiatric and general disability. Journal of Affective Disorders 57, 217-221.
51. Rucci P, Gherardi S, Tansella M, Piccinelli M, Berardi D, Bisoffi G, Corsino MA, Pini S (2003). Subthreshold psychiatric disorders in primary care: prevalence and associated characteristics. Journal of Affective Disorders 76, 171-181.
52. Saarni SI, Harkanen T, Sintonen H, Suvisaari J, Koskinen S, Aromaa A, Lonnqvist J (2006). The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Quality of Life Research 15, 1403-1414.
53. Saarni SI, Suvisaari J, Sintonen H, Pirkola S, Koskinen S, Aromaa A, Lonnqvist J (2007). Impact of psychiatric disorders on health-related quality of life: general population survey. British Journal of Psychiatry 190, 326-332.
54. Scheibe G, Albus M (1997). Predictors and outcome in panic disorder: a 2-year prospective follow-up study. Psychopathology 30, 177-184.
55. Scholten WD, Batelaan NM, van Balkom AJ, Penninx B, Smit JH, van Oppen P (2013). Recurrence of anxiety disorders and its predictors. Journal of Affective Disorders 147, 180-185.
56. Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A (2011). Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. International Clinical Psychopharmacology 26, 75-83.
57. Skapinakis P, Lewis G, Davies S, Brugha T, Prince M, Singleton N (2011). Panic disorder and subthreshold panic in the UK general population: epidemiology, comorbidity and functional limitation. European Psychiatry 26, 354-362.
58. Spak F, Hensing G, Allebeck P (1998). Sick-leave in women with alcohol dependence or abuse: effects of additional psychiatric disorders. Social Psychiatry and Psychiatric Epidemiology 33, 613-619.
59. Stansfeld S, Marmot M (1992). Deriving a survey measure of social support: the reliability and validity of the Close Persons Questionnaire. Social Science and Medicine 35, 1027-1035.
60. Stopa L, Clark DM (2000). Social phobia and interpretation of social events. Behaviour Research and Therapy 38, 273-283.
61. Stout RL, Dolan R, Dyck I, Eisen J, Keller MB (2001). Course of social functioning after remission from panic disorder. Comprehensive Psychiatry 42, 441-447.
62. Tenorio-Martinez R, del Carmen Lara-Munoz M, Elena Medina-Mora M (2009). Measurement of problems in activities and participation in patients with anxiety, depression and schizophrenia using the ICF checklist. Social Psychiatry and Psychiatric Epidemiology 44, 377-384.
63. Twisk JWR (2007). Applied Longitudinal Data Analysis for Epidemiology. A Practical Guide. Cambridge University Press: Cambridge.
64. Üstün TB, Kostanjsek N, Chatterji S, Rehm J (2010). Measuring Health and Disability: Manual for WHO Disability Assessment Schedule (WHODAS 2.0). World Health Organization: Geneva, Switzerland.
65. Van Zuuren FJ (1988). The Fear Questionnaire. Some data on validity, reliability and layout. British Journal of Psychiatry 153, 659-662.
66. Verboom CE, Sentse M, Sijtsema JJ, Nolen WA, Ormel J, Penninx BWJH (2011). Explaining heterogeneity in disability with major depressive disorder: effects of personal and environmental characteristics. Journal of Affective Disorders 132, 71-78.
67. Wacker H, Battegay R, Mullejans R, Schlosser C (eds) (2006) Using the CIDI-C in the General Population. Elsevier Science: Amsterdam.
68. Waghorn G, Chant D, White P, Whiteford H (2005). Disability, employment and work performance among people with ICD-10 anxiety disorders. Australian and New Zealand Journal of Psychiatry 39, 55-66.
69. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S, Ware J (1989). The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. Journal of the American Medical Association 262, 914-919.
70. WHO (2001). International Classification of Functioning, Disability and Health (ICF). World Health Organization: Geneva.
71. Wiebe JS, Christensen AJ (1996). Patient adherence in chronic illness: personality and coping in context. Journal of Personality 64, 815-835.
72. Wilson JK, Rapee RM (2005a). The interpretation of negative social events in social phobia with versus without comorbid mood disorder. Journal of Anxiety Disorders 19, 245-274.
73. Wilson JK, Rapee RM (2005b). The interpretation of negative social events in social phobia: changes during treatment and relationship to outcome. Behaviour Research and Therapy 43, 373-389.
74. Wittchen HU (1994). Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): a critical review. Journal of Psychiatric Research 28, 57-84.
75. Wittchen HU, Burke JD, Semler G, Pfister H, Von Cranach M, Zaudig M (1989). Recall and dating of psychiatric symptoms: test-retest reliability of time-related symptom questions in a standardized psychiatric interview. Archives of General Psychiatry 46, 437-443.
76. Wittchen HU, Fehm L (2003). Epidemiology and natural course of social fears and social phobia. Acta Psychiatrica Scandinavica. Supplementum 417, 4-18.
77. Wittchen HU, Jacobi F (2005). Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies. European Neuropsychopharmacology 15, 357-376.
78. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC (2011). The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology 21, 655-679.
79. Wittchen HU, Robins LN, Cottler LB, Sartorius N, Burke JD, Regier D (1991). Cross-cultural feasibility, reliability and sources of variance of the Composite International Diagnostic Interview (CIDI). British Journal of Psychiatry 159, 645-653.
80. Yonkers KA, Bruce SE, Dyck IR, Keller MB (2003). Chronicity, relapse, and illness-course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depression and Anxiety 17, 173-179.